First Testosterone Undecanoate Softgel Approved by FDA for Hypogonadism
Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.
Hypogonadism
ACP Issues Guidelines for Use of Testosterone Therapy in Age-Related Low Testosterone
The American College of Physicians has issued a set of recommendations to clarify the potential benefits and harms of testosterone therapy in men with age-related low testosterone.
Waist Circumference Affects Coronary Plaque Accumulation in Testosterone Therapy
Older men receiving testosterone treatment with higher waist-to-hip ratio experience greater increases in noncalcified coronary plaque volume.
Short-Term Testosterone Therapy Associated With VTE Risk in Men
For men with and without hypogonadism, testosterone therapy is associated with an increased short-term risk for venous thromboembolism.
Suboptimal Screening for Hypogonadism in Men Receiving Opioids
More men with long-term opioid use are screened for low testosterone than men taking opioids for a short period of time; however, given the known link between opioid use and low testosterone, these rates were still lower than expected.
Managing Opioid-Induced Androgen Deficiency
The increased opioid use has been associated with a rising incidence of opioid-induced endocrinopathy, most commonly in the form of androgen deficiency.
Testosterone Undecanoate May Reduce CV Morbidity, Mortality in Men With Hypogonadism, Type 2 Diabetes
Long-term treatment with testosterone undecanoate was associated with reduced cardiovascular morbidity and mortality in patients with hypogonadism and type 2 diabetes.
Genetically Determined Low Vitamin D Concentrations Associated With Low Testosterone Levels
Genetically low 25-hydroxyvitamin D levels are associated with lower testosterone levels.
Testosterone Deficiencies Common in Men With Hepatitis C Virus Infection
In a subanalysis, researchers discovered that testosterone deficiency was common in men with a sustained virologic response after being treated for hepatitis C.
Testosterone Replacement in Congenital Hypogonadotropic Hypogonadism Has Limited Effects on Bone Health
Testosterone replacement therapy prevents further bone loss at the lumbar and femoral levels in patients with congenital hypogonadotropic hypogonadism, but it does not reliably elevate bone mineral density out of the osteopenic/osteoporotic range.
Next post in Androgen and Reproductive Disorders
